If the answer is 'Yes', you might be a candidate to participate in a clinical study on the treatment of Critical Limb Ischemia (CLI). In this study named ‘Salamander’, a novel cell therapy will be tested.
Critical limb Ischemia is a severe stage of Peripheral Arterial Disease (PAD). Symptoms of CLI include:
The study will evaluate the effects of a new cell therapy that is prepared using your own bone marrow. This study involves an experimental product called REX-001 and a placebo. There is a 33% probability that you will receive the placebo in this study. At the point when all patients participating in the study have had a follow up after 12 months, patients assigned to the placebo group will be offered treatment with REX-001, the experimental product.
REX-001 consists of cells from the patient’s own bone marrow. It is expected to strengthen the quality of existing blood vessels and stimulate the formation of new blood vessels. As a result, the blood flow in the patient’s leg could be significantly improved. The pain at rest that patients experience could be resolved and wounds on toes or feet could heal.